{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06435429\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EmpowHER-303","nct_id":"NCT06435429","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=empowher-303-nct06435429. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of zanidatamab plus physician's choice of chemotherapy (eribulin, or vinorelbine, or gemcitabine, or capecitabine).","label":"Zanidatamab plus physician's choice of chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of trastuzumab plus physician's choice of chemotherapy (eribulin, or gemcitabine, or vinorelbine, or capecitabine).","label":"Trastuzumab plus physician's choice of chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-10-18","type":"ESTIMATED"},"conditions":["Metastatic HER2-positive Breast Cancer"],"enrollment":{"count":550,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zanidatamab","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"DRUG"},{"name":"Eribulin","otherNames":[],"type":"DRUG"},{"name":"Vinorelbine","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-10","lead_sponsor":"Jazz Pharmaceuticals","official_title":"A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Until disease progression or death, up to approximately 44 months"}],"references":[],"start_date":{"date":"2024-08-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06435429"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/empowher-303-nct06435429"}